세계의 당뇨병성 위 마비 치료 시장 보고서(2025년)

Diabetic gastroparesis treatment involves managing delayed stomach emptying in diabetic patients, typically through medications like prokinetics, antiemetics, dietary changes, or, in severe cases, surgical interventions. These treatments aim to alleviate symptoms such as nausea, vomiting, and abdominal discomfort.

The primary treatments for diabetic gastroparesis include medication and surgery. Medications, such as gastroprokinetic agents, antiemetic agents, and botulinum toxin, are utilized for the diagnosis, treatment, prevention, or alleviation of symptoms associated with this medical condition. These medications are administered orally or via injections and are distributed through hospital pharmacies, retail pharmacies, and other channels catering to hospitals, homecare, specialty clinics, and similar healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diabetic gastroparesis treatment market research report is one of a series of new reports from The Business Research Company that provides diabetic gastroparesis treatment market statistics, including diabetic gastroparesis treatment industry global market size, regional shares, competitors with a diabetic gastroparesis treatment market share, detailed diabetic gastroparesis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. This diabetic gastroparesis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic gastroparesis treatment market size has grown steadily in recent years. It will grow from $3.89 billion in 2024 to $4.05 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing diabetes prevalence, limited treatment options, rising awareness and diagnosis, healthcare infrastructure development.

The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $5.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, growing diabetic population, increased research and development, shift in regulatory landscape. Major trends in the forecast period include technological innovations in treatments, emergence of novel therapies, focus on symptom management, telemedicine and remote monitoring, gut microbiome interventions.

The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. gastroenterology care by inflating prices of gastric electrical stimulators and prokinetic drugs developed in Canada and Switzerland, resulting in prolonged digestive complications and higher gastrointestinal(GI) treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The diabetic gastroparesis treatment market is poised for growth, driven by the increasing prevalence of diabetes. The prevalence of diabetes, indicating the percentage of the population diagnosed with diabetes at a specific time, has led to a growing demand for diabetic gastroparesis treatment. This treatment is crucial for managing symptoms and complications associated with gastroparesis, a common complication of diabetes. For example, as of April 2023, The British Diabetic Association reported that 4.3 million individuals in the UK are living with diabetes, with more than 2.4 million at high risk of type 2 diabetes. The registration numbers for 2021-22 reached 148,951, emphasizing the significant impact of diabetes prevalence on the diabetic gastroparesis treatment market.

The growth of the diabetic gastroparesis treatment market is further fueled by the increase in the prediabetic population. Prediabetic individuals, with elevated blood sugar levels not yet meeting the diabetes diagnosis criteria, represent a substantial portion of the population. The emphasis on effective prevention and treatment strategies for diabetes and its complications, including gastroparesis, is evident. For instance, data from the Centers for Disease Control and Prevention in June 2022 revealed that 96 million people aged 18 or older have prediabetes in the United States, constituting 38.0% of the adult population. The significant prediabetic population is a key driver for the growth of the diabetic gastroparesis treatment market.

The increasing volume of surgical procedures is anticipated to drive the growth of the diabetic gastroparesis treatment market in the future. Surgery is a medical specialty that involves treating diseases, injuries, or conditions through operative techniques. Surgical interventions in diabetic patients that can lead to post-surgical gastroparesis include Nissen fundoplication, gastrectomy, gastric bypass surgery, pancreatectomy, vagotomy, and cholecystectomy, which may damage the vagus nerve responsible for coordinating food movement in the digestive tract. For instance, in October 2022, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional organization for board-certified aesthetic plastic surgeons, reported an 11.2% increase in total surgical and non-surgical procedures in 2022, with over 14.9 million surgical and 18.8 million non-surgical procedures conducted globally. Furthermore, in September 2023, the American Society of Plastic Surgeons, a US-based organization focused on plastic surgery, noted that there were 1,498,361 cosmetic surgical procedures performed in 2022. Thus, the rising number of surgical procedures is propelling the diabetic gastroparesis treatment market.

A notable trend in the diabetic gastroparesis treatment market is the development of new medications. Major companies are actively engaged in creating innovative products to maintain their market positions. In June 2023, the U.S. Food and Drug Administration approved two medications, Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride), for treating type 2 diabetes in children aged ten and older. This approval marks a significant advancement in diabetes treatment, offering more comprehensive blood sugar management.

Major companies in the diabetic gastroparesis treatment market are developing advanced solutions, such as small bowel intubation, to improve diagnostic accuracy and treatment efficacy. Small bowel intubation involves the insertion of a tube into the small intestine, allowing for more precise monitoring and therapeutic interventions for conditions like diabetic gastroparesis, which is characterized by impaired gastric motility. For example, in September 2024, Avenacy, a US-based pharmaceutical company, launched Metoclopramide Injection (USP) in the United States. This injectable medication is designed for various indications, particularly to alleviate symptoms associated with diabetic gastroparesis. It helps prevent nausea and vomiting related to chemotherapy and surgical procedures. Additionally, the injection aids in small bowel intubation when traditional methods are unable to pass a tube through the pylorus. It is utilized to stimulate gastric emptying and enhance barium transit during radiological examinations.

Major companies operating in the diabetic gastroparesis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC

North America was the largest region in the diabetic gastroparesis treatment market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Gastroparesis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic gastroparesis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic gastroparesis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic gastroparesis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Surgery
• 2) By Route Of Administration: Oral; Injectables
• 3) By Indication: Compensated Gastroparesis; Gastric Failure
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Prokinetic Agents; Antiemetics; Antidepressants; Other Pharmacological Therapies
• 2) By Surgery: Gastric Electrical Stimulation; Surgical Procedures For Gastric Drainage; Other Surgical Interventions
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Ipca Laboratories Ltd.; Abbott Laboratories; AstraZeneca plc; Medtronics plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Janssen Global Services LLC; Boston Scientific Corporation; Fresenius Kabi AG; Bausch Health Companies Inc.; Salix Pharmaceuticals Inc.; Ironwood Pharmaceuticals Inc.; Wockhardt Ltd.; ANI Pharmaceuticals Inc.; Endologic LLC; Vanda Pharmaceuticals Inc.; Rhythm Pharmaceuticals Inc.; Theravance Biopharma Inc.; Neurogastrx Inc.; Evoke Pharma Inc.; CinRx Pharma LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Gastroparesis Treatment Market Characteristics

3. Diabetic Gastroparesis Treatment Market Trends And Strategies

4. Diabetic Gastroparesis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Diabetic Gastroparesis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Gastroparesis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Gastroparesis Treatment Market Growth Rate Analysis
• 5.4. Global Diabetic Gastroparesis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Gastroparesis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Gastroparesis Treatment Total Addressable Market (TAM)

6. Diabetic Gastroparesis Treatment Market Segmentation

• 6.1. Global Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• 6.2. Global Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• 6.3. Global Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Compensated Gastroparesis
• Gastric Failure
• 6.4. Global Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Diabetic Gastroparesis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prokinetic Agents
• Antiemetics
• Antidepressants
• Other Pharmacological Therapies
• 6.7. Global Diabetic Gastroparesis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastric Electrical Stimulation
• Surgical Procedures For Gastric Drainage
• Other Surgical Interventions

7. Diabetic Gastroparesis Treatment Market Regional And Country Analysis

• 7.1. Global Diabetic Gastroparesis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Gastroparesis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Gastroparesis Treatment Market

• 8.1. Asia-Pacific Diabetic Gastroparesis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Gastroparesis Treatment Market

• 9.1. China Diabetic Gastroparesis Treatment Market Overview
• 9.2. China Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Gastroparesis Treatment Market

• 10.1. India Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Gastroparesis Treatment Market

• 11.1. Japan Diabetic Gastroparesis Treatment Market Overview
• 11.2. Japan Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Gastroparesis Treatment Market

• 12.1. Australia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Gastroparesis Treatment Market

• 13.1. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Gastroparesis Treatment Market

• 14.1. South Korea Diabetic Gastroparesis Treatment Market Overview
• 14.2. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Gastroparesis Treatment Market

• 15.1. Western Europe Diabetic Gastroparesis Treatment Market Overview
• 15.2. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Gastroparesis Treatment Market

• 16.1. UK Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Gastroparesis Treatment Market

• 17.1. Germany Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Gastroparesis Treatment Market

• 18.1. France Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Gastroparesis Treatment Market

• 19.1. Italy Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Gastroparesis Treatment Market

• 20.1. Spain Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Gastroparesis Treatment Market

• 21.1. Eastern Europe Diabetic Gastroparesis Treatment Market Overview
• 21.2. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Gastroparesis Treatment Market

• 22.1. Russia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Gastroparesis Treatment Market

• 23.1. North America Diabetic Gastroparesis Treatment Market Overview
• 23.2. North America Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Gastroparesis Treatment Market

• 24.1. USA Diabetic Gastroparesis Treatment Market Overview
• 24.2. USA Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Gastroparesis Treatment Market

• 25.1. Canada Diabetic Gastroparesis Treatment Market Overview
• 25.2. Canada Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Gastroparesis Treatment Market

• 26.1. South America Diabetic Gastroparesis Treatment Market Overview
• 26.2. South America Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Gastroparesis Treatment Market

• 27.1. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Gastroparesis Treatment Market

• 28.1. Middle East Diabetic Gastroparesis Treatment Market Overview
• 28.2. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Gastroparesis Treatment Market

• 29.1. Africa Diabetic Gastroparesis Treatment Market Overview
• 29.2. Africa Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Gastroparesis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Gastroparesis Treatment Market Competitive Landscape
• 30.2. Diabetic Gastroparesis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ipca Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Gastroparesis Treatment Market Other Major And Innovative Companies

• 31.1. Medtronics plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Janssen Global Services LLC
• 31.6. Boston Scientific Corporation
• 31.7. Fresenius Kabi AG
• 31.8. Bausch Health Companies Inc.
• 31.9. Salix Pharmaceuticals Inc.
• 31.10. Ironwood Pharmaceuticals Inc.
• 31.11. Wockhardt Ltd.
• 31.12. ANI Pharmaceuticals Inc.
• 31.13. Endologic LLC
• 31.14. Vanda Pharmaceuticals Inc.
• 31.15. Rhythm Pharmaceuticals Inc.

32. Global Diabetic Gastroparesis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Gastroparesis Treatment Market

34. Recent Developments In The Diabetic Gastroparesis Treatment Market

35. Diabetic Gastroparesis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Gastroparesis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Gastroparesis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Gastroparesis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer